Directorio de personas
Jose Manuel Valdivielso Revilla

Jose Manuel Valdivielso Revilla

Grado: Doctor/a

973 702 952
valdivielso(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/B-5673-2009

Grupos

Publicaciones

  • Mota-Zamorano S; Robles NR; González LM; Valdivielso JM; Lopez-Gomez J; Cancho B; García-Pino G; Gervasini G

    Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy.

    Journal of Clinical Medicine 10 -. .

    [doi:10.3390/jcm10173980]

  • Valdivielso, JM; Balafa, O; Ekart, R; Ferro, CJ; Mallamaci, F; Mark, PB; Rossignol, P; Sarafidis, P; del Vecchio, L; Ortiz, A

    Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies

    DRUGS 81 1467-1489. .

    [doi:10.1007/s40265-021-01555-5]

  • González LM; Robles NR; Mota-Zamorano S; Valdivielso JM; López-Gómez J; Gervasini G

    Genetic Variants in PGE2 Receptors Modulate the Risk of Nephrosclerosis and Clinical Outcomes in These Patients.

    Journal of Personalized Medicine 11 -. .

    [doi:10.3390/jpm11080772]

  • Vila MDM; Remeseiro B; Igual L; Elosua R; Ramos R; Valdivielso JM; Martí-Lluch R; Marrugat J; Grau M

    Do individuals with autoimmune disease have increased risk of subclinical carotid atherosclerosis and stiffness?

    HYPERTENSION RESEARCH 44 978-987. .

    [doi:10.1038/s41440-021-00655-9]

  • Del Mar Vila M; Remeseiro B; Igual L; Elosua R; Ramos R; Valdivielso JM; Martí-Lluch R; Marrugat J; Grau M

    Correction: Do individuals with autoimmune disease have increased risk of subclinical carotid atherosclerosis and stiffness?

    HYPERTENSION RESEARCH 44 1046-1046. .

    [doi:10.1038/s41440-021-00664-8]

  • Saumoy, M; Di Yacovo, S; Perez, S; Sanchez-Quesada, JL; Valdivielso, JM; Subirana, I; Imaz, A; Tiraboschi, JM; Garcia, B; Ordonez-LLanos, J; Benitez, S; Podzamczer, D; Grau, M

    Carotid atherosclerosis in virologically suppressed HIV patients: comparison with a healthy sample and prediction by cardiovascular risk equations

    HIV MEDICINE 22 581-591. .

    [doi:10.1111/hiv.13093]

  • Bozic, Milica; Diaz-Tocados, Juan M.; Bermudez-Lopez, Marcelino; Forne, Carles; Martinez, Cristina; Fernandez, Elvira; Valdivielso, Jose M.

    Independent effects of secondary hyperparathyroidism and hyperphosphatemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.

    NEPHROLOGY DIALYSIS TRANSPLANTATION 37 1-10. .

    [doi:10.1093/ndt/gfab184]

  • Rodrigues-Diez, RR; Tejera-Munoz, A; Orejudo, M; Marquez-Exposito, L; Santos, L; Rayego-Mateos, S; Cantero-Navarro, E; Tejedor-Santamaria, L; Marchant, V; Ortiz, A; Egido, J; Mezzano, S; Selgas, R; Navarro-Gonzalez, JF; Valdivielso, JM; Lavoz, C; Ruiz-Ortega, M

    Interleukin-17A: Potential mediator and therapeutic target in hypertension.

    Nefrologia 41 244-257. .

    [doi:10.1016/j.nefro.2020.11.009]

  • Fernandez, LM; Sanchez-Alvarez, JE; de la Tassa, CM; Fernandez, JJB; Maria, V; Fernandez, E; Valdivielso, JM; Betriu, A

    Risk factors associated with valvular calcification in patients with chronic kidney disease. Analysis of NEFRONA study

    Nefrologia 41 337-346. .

    [doi:10.1016/j.nefro.2020.08.012]

  • Kosanovic M; Llorente A; Glamoclija S; Valdivielso JM; Bozic M

    Extracellular Vesicles and Renal Fibrosis: An Odyssey toward a New Therapeutic Approach.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 22 -. .

    [doi:10.3390/ijms22083887]

  • Del Vecchio, L; Ekart, R; Ferro, CJ; Malyszko, J; Mark, PB; Ortiz, A; Sarafidis, P; Valdivielso, JM; Mallamaci, F; ERA-EDTA European Renal and Cardiovascular Medicine Working (EURECA-m) Group

    Intravenous iron therapy and the cardiovascular system: risks and benefits.

    CLINICAL KIDNEY JOURNAL 14 1067-1076. .

    [doi:10.1093/ckj/sfaa212]

  • Gorriz JL; Arroyo D; D'Marco L; Torra R; Tomás P; Puchades MJ; Panizo N; Pantoja J; Montomoli M; Llisterri JL; Pallares-Carratalá V; Valdivielso JM

    Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease.

    BMC NEPHROLOGY 22 110-110. .

    [doi:10.1186/s12882-021-02313-1]

Proyectos

  • Calprotectin as a new companion biomarker and associated drug target for premature vascular aging in chronic kidney disease and type 2 diabetes
  • Estancias de personal docente y/o investigador senior en centros extranjeros 2022
  • El primer Estudio de asociación de genoma completo (GWAS) con enfermedad coronaria poblacional a 10 años en más de 100.000 participantes para personalizar la prevención cardiovascular en España
  • Influence of SARS-COV-2 infection in atherosclerosis development. “El BUS DE LA SALUT” study
  • SPAIN CKD CAUSE (SPACKDC)
  • INVESTIGO 2022: Grup de recerca translacional vascular i renal
  • Papel de PTEN en la reabsorcion tubular renal de proteinas. Implicaciones en nefropatias proteinuricas
  • Preservació la membrana peritoneal abordant noves vies per inhibir la transició mesotelio-mesenquimal.
  • Acciones de Dinamización "Europa Investigación 2020"
  • Contratos Sara Borrell
  • Papel de la vía PI3K/AKT/mTOR en la regulación de las alteraciones del metabolismo mineral en la enfermedad renal crónica. Implicaciones en la regulación de la síntesis de FGF23.
  • Ajuts destinats a contractar personal investigador novell (FI)